{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:35:20Z","timestamp":1761744920619},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.2169\/internalmedicine.1585-18","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T22:31:44Z","timestamp":1545085904000},"page":"949-953","source":"Crossref","is-referenced-by-count":4,"title":["Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy"],"prefix":"10.2169","volume":"58","author":[{"given":"Yasuki","family":"Nagai","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takekazu","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kozawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taka-aki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Iwahashi","sequence":"additional","affiliation":[{"name":"Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (I), Osaka Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 14: 675-688, 2012."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Drucker DJ. The biology of incretin hormones. Cell Metab 3: 153-165, 2006.","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. diabetes 59: 1030-1037, 2010.","DOI":"10.2337\/db09-1694"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wattergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673, 1993.","DOI":"10.1007\/BF01316798"},{"key":"5","unstructured":"5. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstr\u00f6m PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43: 2284-2290, 1998."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111: 117-121, 2006.","DOI":"10.1016\/j.brainres.2006.06.090"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 45: 570-577, 2005.","DOI":"10.1177\/0091270004274432"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 45: 1032-1037, 2005.","DOI":"10.1177\/0091270005278806"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy asian men. J Clin Pharmacol 46: 1179-1187, 2006.","DOI":"10.1177\/0091270006291622"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kothare PA, Linnebjerg H, Skrivanek Z, et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther 45: 114-120, 2007.","DOI":"10.5414\/CPP45114"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Clin Pharmacol Ther 47: 651-658, 2009.","DOI":"10.5414\/CPP47651"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide--a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol\/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol 51: 1696-1703, 2011.","DOI":"10.1177\/0091270010389471"},{"key":"13","unstructured":"13. Kothare PA, Seger ME, Northrup J, et al. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol 12: 8, 2012."},{"key":"14","unstructured":"14. Fujita Y, Kitamura T, Otsuki M, et al. Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency. Diabetes Care 36: e8, 2013."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Asakawa H, Onishi M, Hayashi I, Fukuda A, Tokunaga K. Comparison between coefficient of R-R interval variation and gastric emptying in type 2 diabetes mellitus patients. J Gastroenterol Hepatol 20: 1358-1364, 2005.","DOI":"10.1111\/j.1440-1746.2005.04025.x"},{"key":"16","unstructured":"16. Kitamura T, Otsuki M, Kubo N, et al. Two cases of paralytic ileus associated with the administration of liraglutide. Tonyobyo (Diabetes) 55: 982-986, 2012 (in Japanese, Abstract in English)."},{"key":"17","unstructured":"17. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93: 1526-1540, 2008."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ma RC, Chan WB, So WY, et al. Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome. BMJ 330: 299-300, 2005.","DOI":"10.1136\/bmj.330.7486.299"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kyriazopoulou V, Vagenakis AG. Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. J Clin Endocrinol Metab 75: 315-317, 1992.","DOI":"10.1210\/jcem.75.1.1619024"},{"key":"20","unstructured":"20. Nickelsen T, Lissner W, Sch\u00f6ffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol 94: 275-280, 1989."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/7\/58_1585-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:16:36Z","timestamp":1559362596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/7\/58_1585-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1585-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}